drugset / Trial / NCT00202969

Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer

NCT00202969

Phase 3 Completed 180 enrolled Taiho Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, three arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1 alone compared with S-1 plus CDDP, and S-1 plus CDDP compared with 5-FU plus CDDP in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1:1) to S-1 (Arm A), S-1/CDDP (Arm B) or 5-FU/CDDP (Arm C). Patients will be stratified to achieve balanced distribution of patients to each arm according to following stratifications, performance status (0, 1, or 2), the number of metastatic sites (1 vs \>1), prior gastrectomy, and center.

Timeline

Start
2005-07
Primary completion
2007-01
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 20 mg/m2 Intravenous
Comparator Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg/m2 Oral
Comparator fluorouracil Small molecule 600 mg/m2 Intravenous

Indications